{"slug":"pt-141-tirzepatide","verification":{"valid":true,"entries":2,"head":"afe35fbca0efc14ba55a1a4e9f34b6447a71584eae54e3a258ab4ae557e109a5"},"energy":{"passes":2,"tokens_in":38776,"tokens_out":3596,"tokens_total":42372,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"afe35fbca0efc14ba55a1a4e9f34b6447a71584eae54e3a258ab4ae557e109a5"},"provenance":[{"ts":"2026-06-30T01:06:14.531Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Tirzepatide\nSlug: pt-141-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"},{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"},{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical over","response":"{\n  \"slug\": \"pt-141-tirzepatide\",\n  \"title\": \"PT-141 and Tirzepatide: Evidence-Graded Look at Sexual Arousal Pathways and Metabolic Load Reduction\",\n  \"body\": \"## What's breaking down\\n\\nNo single named degenerative condition matches the slug. Layers inferred from the compound cross and available claims center on two distinct areas: central nervous system arousal and desire pathways, plus metabolic and body-weight driven mechanical stress. PT-141 targets melanocortin receptors involved in sexual motivation. Tirzepatide targets GLP-1 and GIP receptors tied to appetite, glucose control, and weight reduction. When these layers interact, reduced desire reported by some Tirzepatide users may compound other quality-of-life effects even as weight drops.\\n\\n## Why PT-141 might help you\\n\\nIf central arousal or desire is the layer you track, PT-141 is discussed because it acts on melanocortin pathways in the brain rather than blood flow alone. Human data show statistically significant gains in sexual desire scores versus placebo in premenopausal women with hypoactive sexual desire disorder. One phase 3 program measured increases in satisfying sexual events and drops in distress. For men, smaller studies and crossover designs found enhanced erectile duration when PT-141 was added to sildenafil, with effects starting around 30 minutes. The mechanism differs from vascular agents, so the logic runs: if desire or central initiation is the bottleneck, this pathway is the one studied. Animal and mechanistic work supports melanocortin receptor activation leading to downstream arousal signals, yet human approval rests on the female HSDD trials.\\n\\n## Why Tirzepatide might help you\\n\\nIf excess body weight or related metabolic load forms part of the picture, Tirzepatide is discussed because it produces clinically meaningful weight loss through GLP-1/GIP agonism. Phase 3 trials documented average losses exceeding 15 % body weight at higher doses. One pound lost corresponds to roughly f","tokens_in":38776,"tokens_out":3596,"cost":0,"prev":"genesis","hash":"c5b318f5b4ff5999e32c9e394ce98ffc2a11db71c0012cce469230d40948118a"},{"ts":"2026-07-17T02:41:12.132Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c5b318f5b4ff5999e32c9e394ce98ffc2a11db71c0012cce469230d40948118a","hash":"afe35fbca0efc14ba55a1a4e9f34b6447a71584eae54e3a258ab4ae557e109a5"}]}